Announcements Trials

Browse Landscape

Status

Sponsor Class

Study Type

Observational 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 121 Breast Neoplasms 83 Colorectal Neoplasms 52 Stomach Neoplasms 42 Pancreatic Neoplasms 42 Lung Neoplasms 41 Rectal Neoplasms 38 Neoplasm Metastasis 36 Neoplasms 33 Esophageal Squamous Cell Carcinoma 32 Esophageal Neoplasms 31 Head and Neck Neoplasms 26 Squamous Cell Carcinoma of Head and Neck 23 Ovarian Neoplasms 23 Triple Negative Breast Neoplasms 21 Nasopharyngeal Carcinoma 20 Recurrence 18 Leukemia, Myeloid, Acute 18 Colonic Neoplasms 18 Uterine Cervical Neoplasms 17 Precursor Cell Lymphoblastic Leukemia-Lymphoma 17 Small Cell Lung Carcinoma 15 Glioblastoma 15 Lymphoma 12 Prostatic Neoplasms 11 Fallopian Tube Neoplasms 11 Carcinoma, Squamous Cell 11 Brain Neoplasms 11 Sarcoma 10 NSCLC 9

Interventions

pyrotinib 2 pertuzumab 2 Trastuzumab 2 disitamab vedotin 1 atezolizumab 1 RC48 antibody 1 Drug Therapy 1 Capecitabine 1 Ado-Trastuzumab Emtansine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × HER2-positive Metastatic Breast Cancer × Drug Therapy × Clear all

NCT05188495 2022-01-12

HELP

Peking University Cancer Hospital & Institute

HER2-positive Metastatic Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡